CSIMarket
 


Jasper Therapeutics Inc   (JSPR)
Other Ticker:  
 

Jasper Therapeutics Inc 's Leverage Ratio

JSPR's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 16.52%, Leverage Ratio fell to 0.17, below the Jasper Therapeutics Inc 's average Leverage Ratio.

Within Biotechnology & Pharmaceuticals industry in the third quarter 2023, 29 other companies have achieved lower Leverage Ratio than Jasper Therapeutics Inc in the III Quarter 2023. While Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 296 to 378 .

Explain Leverage Ratio?
Who are JSPR Customers?
What are JSPR´s Total Liabilities?


JSPR Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Change 97.9 % 87.48 % 83.83 % -48.23 % -39.49 %
Y / Y Total Liabilities Change 40.94 % 20.54 % 8.97 % -48.74 % -59.65 %
Leverage Ratio MRQ 0.17 0.13 0.11 0.34 0.24
JSPR's Total Ranking # 378 # 296 # 225 # 677 # 620
Seq. Equity Change -14.58 % -11.98 % 247.88 % -24.34 % -19.08 %
Seq. Total Liabilities Change 16.52 % 2.99 % 9.59 % 7.16 % -0.35 %



Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 30
Healthcare Sector # 196
Overall Market # 378


Leverage Ratio Statistics
High Average Low
19.11 2.12 0.11
(Jun 30 2021)   (Mar 31 2023)




Financial Statements
Jasper Therapeutics Inc 's Equity $ 94 Millions Visit JSPR's Balance sheet
Jasper Therapeutics Inc 's Total Liabilities $ 16 Millions Visit JSPR's Balance sheet
Source of JSPR's Sales Visit JSPR's Sales by Geography


Cumulative Jasper Therapeutics Inc 's Leverage Ratio

JSPR's Leverage Ratio for the trailling 12 Months

JSPR Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity TTM Growth 97.9 % 87.48 % 83.83 % -48.23 % -39.49 %
Y / Y Total Liabilities TTM Growth 40.94 % 20.54 % 8.97 % -48.74 % -59.65 %
Leverage Ratio TTM 0.15 0.16 0.18 0.23 0.24
Total Ranking TTM # 2 # 244 # 3 # 225 # 2
Seq. Equity TTM Growth -14.58 % -11.98 % 247.88 % -24.34 % -19.08 %
Seq. Total Liabilities TTM Growth 16.52 % 2.99 % 9.59 % 7.16 % -0.35 %


On the trailing twelve months basis Despite of the net new borrowings of 16.52% during the twelve months period ending in III Quarter 2023 Jasper Therapeutics Inc has managed to decrease Leverage Ratio in the III Quarter 2023 to 0.15, a new company low.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry JSPR recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has improved so far to 2, from total ranking in previous 12 month period at 244.

Explain Leverage Ratio?
Who are JSPR Customers?
What are JSPR´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 0
Healthcare Sector # 1
Within the Market # 2


trailing twelve months Leverage Ratio Statistics
High Average Low
0.77 0.34 0.15
(Dec 31 2021)  




Companies with similar Leverage Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Equity
Moderna Inc   0.45 $ 5,995.000  Millions$ 13,455.000  Millions
Qiagen N v   0.44 $ 1,692.857  Millions$ 3,807.764  Millions
Recursion Pharmaceuticals Inc   0.44 $ 192.858  Millions$ 437.967  Millions
Neurocrine Biosciences Inc   0.42 $ 846.100  Millions$ 2,002.100  Millions
Scholar Rock Holding Corp  0.41 $ 69.489  Millions$ 167.665  Millions
Instil Bio Inc   0.40 $ 94.426  Millions$ 234.024  Millions
Editas Medicine Inc   0.40 $ 144.188  Millions$ 360.462  Millions
Tscan Therapeutics Inc   0.39 $ 65.380  Millions$ 168.961  Millions
Ikena Oncology Inc   0.39 $ 59.991  Millions$ 155.344  Millions
Seagen Inc   0.37 $ 954.716  Millions$ 2,550.421  Millions
Monte Rosa Therapeutics Inc   0.37 $ 67.579  Millions$ 184.524  Millions
Sophia Genetics Sa  0.36 $ 54.714  Millions$ 151.442  Millions
Bioatla Inc   0.36 $ 34.006  Millions$ 94.703  Millions
Cognition Therapeutics inc   0.34 $ 9.846  Millions$ 28.926  Millions
Passage Bio inc   0.34 $ 42.980  Millions$ 126.276  Millions
Organovo Holdings Inc   0.32 $ 2.705  Millions$ 8.456  Millions
Fusion Pharmaceuticals Inc   0.31 $ 58.740  Millions$ 188.471  Millions
Entera Bio Ltd   0.31 $ 1.927  Millions$ 6.236  Millions
Graphite Bio Inc   0.30 $ 62.209  Millions$ 204.019  Millions
Bio techne Corp  0.28 $ 567.754  Millions$ 1,997.746  Millions
Black Diamond Therapeutics Inc   0.28 $ 38.065  Millions$ 134.317  Millions
Adverum Biotechnologies Inc   0.28 $ 28.856  Millions$ 102.714  Millions
Solid Biosciences Inc   0.28 $ 40.367  Millions$ 144.361  Millions
Allovir Inc   0.27 $ 52.978  Millions$ 195.334  Millions
Exelixis Inc   0.27 $ 629.290  Millions$ 2,347.620  Millions
Repligen Corp  0.26 $ 522.257  Millions$ 1,988.557  Millions
Tarsus Pharmaceuticals Inc   0.26 $ 54.668  Millions$ 213.664  Millions
Vor Biopharma Inc   0.25 $ 44.499  Millions$ 174.781  Millions
Iovance Biotherapeutics Inc   0.25 $ 167.839  Millions$ 674.008  Millions
Twist Bioscience Corporation  0.25 $ 152.971  Millions$ 623.432  Millions

Date modified: 2024-01-10T05:56:45+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com